Lori Ann Cox
Penn State Milton S. Hershey Medical Center(US)
Publications by Year
Research Areas
Hair Growth and Disorders, melanin and skin pigmentation, Autoimmune Bullous Skin Diseases, Cutaneous lymphoproliferative disorders research, Atherosclerosis and Cardiovascular Diseases
Most-Cited Works
- → A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results(2021)185 cited
- → Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial(2022)134 cited
- → Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers(2021)92 cited
- → Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study(2017)91 cited
- → Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate(2020)86 cited
- → Increased Microchimeric CD4+ T Lymphocytes in Peripheral Blood from Women with Systemic Sclerosis(2002)68 cited
- → The public’s attitude and perception concerning witnessed cardiopulmonary resuscitation*(2006)55 cited
- → Detection of cellular microchimerism of male or female origin in systemic sclerosis patients by polymerase chain reaction analysis of HLA–Cw antigens(2000)55 cited
- → Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial(2021)42 cited
- → Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus(2015)29 cited